Due to their involvement as checkpoints in immune cell responses, the Sialic-acid-binding immunoglobulin-like lectins or Siglecs have gain more and more interest as a therapeutic targets in Immune-Oncology and Immune regulation. To support researchers in their research BPS Bioscience have developed and released a number of Siglec proteins and stable cell lines, available in Europe through tebu-bio.